FORM 4

Check this box if no longer subject

to Section 16. Form 4 or Form 5 obligations may continue. See

Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Ballaron Craig						2. Issuer Name and Ticker or Trading Symbol Verrica Pharmaceuticals Inc. [VRCA]									k all app Direc	tor	ng Per	rson(s) to Is 10% Ov Other (s	wner
(Last) (First) (Middle) C/O VERRICA PHARMACEUTICALS INC. 10 NORTH HIGH STREET, SUITE 200						3. Date of Earliest Transaction (Month/Day/Year) 08/24/2020										Officer (give title below)		below)	specify
(Street) WEST CHESTE			9380		4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Line) X Form filed by One Reporting Per Form filed by More than One Reperson										orting Pers	on		
(Oity)	(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day					tion	ion 2A. Deemed Execution Date,			3. 4. Securities Acquired (ADDISPOSED OF (D) (Instr. 3 Code (Instr. 8)			ired (A	o) or 5. Amo 4 and Securi Benefi		ount of ties cially I Following	Form (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	Amount	(A) (D)	or Pr	ice	Transa	saction(s) . 3 and 4)			(1130.4)				
Common	Common Stock 08/24/2					2020					5,228	A	\$	9.16 ⁽¹⁾	5,228			D	
Common Stock 08/25/2					2020				P		4,772	A	. \$	3.57 ⁽²⁾	57 ⁽²⁾ 10,000		D		
		Tal									osed of, convertib				Owne	d			
1. Title of Derivative Security (Instr. 3)	rivative Conversion Date Execution Da curity or Exercise (Month/Day/Year) if any			ion Date,	4. Transaction Code (Instr. 8)		of Deriv Secu Acqu (A) o Dispo	r osed) r. 3, 4	Expirati	5. Date Exercisable and Expiration Date Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		De Se (In	Price of rivative curity str. 5)	9. Number derivative Securities Beneficial! Owned Following Reported Transactio (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code V		(A)	(D)	Date Exercisable		Expiration Date	or Numb of Title Share							

Explanation of Responses:

- 1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$9.03 to \$9.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2).
- 2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$8.45 to \$8.81 inclusive.

Remarks:

/s/ Mark Ballantyne, Attorneyin-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.